Award-winning medtech firm, Glyconics© has successfully completed two independent clinical studies to validate the performance and safety of its novel non-invasive diabetes screening device. The currently embargoed ANODE01 and ANODE02 diabetes programme results will be formally announced at the annual meeting of the American Diabetes Association (ADA) in June. Glyconics’ Chief Medical Officer, Dr Päivi […]
The post Glyconics©’ novel non-invasive diabetes screening device meets primary endpoints in two clinical investigations appeared first on .
